Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research

Abstract 5610: Epigallocatechin 3-gallate (EGCG) as a natural product (NP) with potent antitumor activity against human ovarian cancer

Derek M. Johnson, Anthony E. Staren, Timothy C. Birdsall, Edgar D. Staren and Donald P. Braun
Derek M. Johnson
1Cancer Treatment Ctrs. of America, Zion, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony E. Staren
1Cancer Treatment Ctrs. of America, Zion, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy C. Birdsall
1Cancer Treatment Ctrs. of America, Zion, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edgar D. Staren
1Cancer Treatment Ctrs. of America, Zion, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald P. Braun
1Cancer Treatment Ctrs. of America, Zion, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-5610 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

A substantial challenge in the practice of integrative cancer treatment is to identify active combinations of natural products (NPs) that can collaborate with conventional treatment modalities to achieve enhanced tumor control. This approach is especially attractive for tumors that are inherently chemoresistant or become chemoresistant as a consequence of multidrug resistance. But it has been difficult to prove efficacy of combining NPs with conventional treatment such as chemotherapy due in large part to the challenges inherent in conducting controlled clinical trials with combination regimens. These challenges provide a rationale for translational research studies to characterize effects of NPs on tumor processes relevant to chemoresistance. The current study investigated the activity of Epigallocatechin 3-gallate (EGCG), the principal polyphenol from green tea extract to modulate tumor proliferation and sensitivity to antitumor immunity in human ovarian cancer cells. Tumor proliferation was assessed with a standard MTS assay using the ATCC cell line, OvCar 3 as well as single cell suspensions prepared from human ovarian cancer surgical specimens. Sensitivity to IL2-activated human lymphocytes was assessed with a standard, 4 hr 51Chromium-release assay. EGCG produced a dose-dependent inhhibition of proliferation of the OvCar 3 cell line ranging from <5% (10 ug/mL) through 33% (30 ug/mL). Notably, these concentrations of EGCG are all achievable pharmacologically with a dose of 8, 200 mg capsules daily. Dose dependent inhibition of proliferation was also observed with cells from human ovarian cancer specimens with inhhibition ranging from 10.5% (5 ug/mL) to as much as 54% (25 ug/mL). The effects of EGCG were found to collaborate with pharmacologically achievable concentrations of both cisplatinum (Pt; 500 ng/mL) and gemcitabine (Gz; 10 ng/mL). Thus, 24%, 21% and 60% inhibition of OvCar 3 cells was observed with Pt, EGCG and Pt+EGCG respectively. The corresponding values were 30%, 34%, and 50% inhibition for Gz, EGCG, and Gz+EGCG. Additional effects of EGCG on OvCar 3 were shown in studies using EGCG pre-treatment of target cells prior to testing sensitivity to lysis by IL2-activated human lymphocytes. The results showed that EGCG pretreatment, in doses that did not reduce cell number or inhibit prolliferation over 72 hrs rendered the cells 53% more sensitive to lysis in the 51Chromium-release assay. These results demonstrate direct effects of the principal polyphenol of green tea extract on both the proliferative and immunologic sensitivitiy of human ovarian cancer cells. That these effects can collaborate with chemotherapeutic agents commonly used in the treatment of ovarian cancer patients suggests that combination regimens of this NP with cancer chemotherapy may be valuable in patients for both adjuvant therapy and for maintenance of remission.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5610.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 5610: Epigallocatechin 3-gallate (EGCG) as a natural product (NP) with potent antitumor activity against human ovarian cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 5610: Epigallocatechin 3-gallate (EGCG) as a natural product (NP) with potent antitumor activity against human ovarian cancer
Derek M. Johnson, Anthony E. Staren, Timothy C. Birdsall, Edgar D. Staren and Donald P. Braun
Cancer Res April 15 2010 (70) (8 Supplement) 5610; DOI: 10.1158/1538-7445.AM10-5610

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 5610: Epigallocatechin 3-gallate (EGCG) as a natural product (NP) with potent antitumor activity against human ovarian cancer
Derek M. Johnson, Anthony E. Staren, Timothy C. Birdsall, Edgar D. Staren and Donald P. Braun
Cancer Res April 15 2010 (70) (8 Supplement) 5610; DOI: 10.1158/1538-7445.AM10-5610
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research

  • Abstract SY20-03: Novel radiotracers for clinical molecular imaging in oncology
  • Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy
  • Abstract SS02-04: How much can we afford to pay for new drugs, and how do we make those decisions?
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Immunomodulatory Agents and Interventions

  • Abstract 5615: Effects of corticosteroids on tumor immunity induced by anti-CTLA-4 mAb therapy in a mouse model
  • Abstract 5612: Pretreatment with chemotherapy can enhance the immunogenicity of tumors by promoting adaptive immune responses
  • Abstract 5609: Resveratrol as a modulator of human tumor proliferation and immunologic sensitivity
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement